Introduction

Trigger point injections (TPI) and transforaminal epidural injections are treatments used to manage chronic pain. These injections contain a solution of a pain-numbing, steroid, and/or anti-inflammatory medication. TPIs are given to painful areas of muscle that contain trigger points or knots of muscle that form when muscles fail to relax. An epidural is an injection that is given in the space just outside the membrane that protects the spinal cord. A transforaminal epidural injection numbs the spinal nerves and can also be used to diagnose the type of pain the patient is experiencing. This policy describes when trigger point and transforaminal epidural injections may be considered medically necessary.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.
<table>
<thead>
<tr>
<th>Injection</th>
<th>Medical Necessity</th>
</tr>
</thead>
</table>
| **Trigger point injections**    | **Trigger point injections may be considered medically necessary for the following indications:**  
  • Established myofascial pain syndrome (MPS) which is unresponsive to noninvasive medical management (eg, analgesics, passive physical therapy, ultrasound, range of motion, and active exercises)  
  • As a bridging therapy to relieve pain while other treatments are also initiated such as medication or physical therapy  
  • As a single therapeutic maneuver when joint movement is mechanically blocked (ie, coccygeus muscle)  
  
  **Note:** See Related Information below for Limitations                                                                                                                                 |
| **Transforaminal epidural injections** | **Transforaminal epidural injections may be considered medically necessary for the following:**  
  • Diagnostic Indications:  
    o When there is a question of intercostal neuralgia versus thoracic facet syndrome  
    o When radiologic studies have demonstrated an abnormality limited to an adjacent nerve root  
    o When a clinical picture is suggestive, but not typical, for both nerve root and distal nerve or joint disease and multiple sources of pain are in question (eg, there is a root dysfunction from mild lumbar disc disease versus a causalgia-like syndrome from an old, chronic knee injury)  
    o When a discrepancy exists between the demonstrated pathology and the complaint or findings (eg, when the source of pain appears to be due to a classic monoradiculopathy, yet the neurodiagnostic studies have failed to provide a structural explanation or an L4 disc bulge is seen, radiologically, with an S1 root syndrome).  
    o To determine if the cause of pain is central or peripheral as in leg pain following a spinal cord injury  
  • Therapeutic Indications:  
    o When radicular pain is resistant to, or there is a contraindication to other therapeutic measures (eg, non-narcotic analgesic, physical therapy, etc.) |
### Injection

<table>
<thead>
<tr>
<th>Medical Necessity</th>
</tr>
</thead>
<tbody>
<tr>
<td>o When surgery is contraindicated</td>
</tr>
<tr>
<td>o When treatment of acute herpes zoster pain or post-herpetic neuralgia is needed</td>
</tr>
<tr>
<td>o When there is reflex sympathetic dystrophy (RSD), causalgia or a complex regional pain syndrome I and II, in lieu of a sympathetic blockade</td>
</tr>
<tr>
<td>o When there is monoradicular pain confirmed by diagnostic blockade in which a surgically correctable lesion cannot be identified</td>
</tr>
<tr>
<td>o When post-decompressive radiculitis or post-surgical scarring exists</td>
</tr>
</tbody>
</table>

**Note:** See Related Information below for **Limitations**

### Coding

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td></td>
</tr>
<tr>
<td>20552</td>
<td>Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s)</td>
</tr>
<tr>
<td>20553</td>
<td>Injection(s); single or multiple trigger point(s), 3 or more muscles</td>
</tr>
<tr>
<td>64479</td>
<td>Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with imaging guidance (fluoroscopy or CT); cervical or thoracic, single level</td>
</tr>
<tr>
<td>64480</td>
<td>Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with imaging guidance (fluoroscopy or CT); cervical or thoracic, each additional level (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>64483</td>
<td>Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with imaging guidance (fluoroscopy or CT); lumbar or sacral, single level</td>
</tr>
<tr>
<td>64484</td>
<td>Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with imaging guidance (fluoroscopy or CT); lumbar or sacral, each additional level (List separately in addition to code for primary procedure)</td>
</tr>
</tbody>
</table>

**Note:** CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).
Related Information

Limitations

**Trigger Point Injections (TPI)**

- TPI is not covered more often than three sessions in a three-month period (medical necessity for additional injections must be documented in the medical record and available upon request). TPI is not covered if it is not indicated or not medically necessary.

- Medical record documentation must support the medical necessity, frequency and patient response to TPI and be available upon request.

- Only one code from 20552 to 20553 should be reported on a given day, no matter how many sites or regions are injected.

- When a given site is injected, it will be considered one injection service regardless of the number of injections administered.

- The passage of electrical current through acupuncture needles is not covered.

- Prolotherapy is not a covered service, and billing under the trigger point injection code is a misrepresentation of the actual service performed.

**Transforaminal Epidural Injections**

- Medical record documentation must support the medical necessity, frequency of transforaminal epidural injections and patient response. This documentation must be available upon request. Transforaminal epidural injections are not covered if not indicated or not medically necessary.

- Transforaminal epidural injections, whether diagnostic or therapeutic, must be in keeping with the most current evidence-based practice guidelines.

- Not indicated for low back pain associated with myofascial pain syndrome.

- Not indicated for the treatment of a soft-tissue source of pain in which no nerve root pathology exists.
• Due to the inherent risks associated with transforaminal epidural injections, physicians performing this service should have substantial and specific experience performing this procedure and a clear understanding of the risks involved.

• Fluoroscopic guidance or computed tomography (CT) guided imaging must be utilized in the performance of transforaminal epidural injections to ensure precise placement of the needle and medications.

• Provision of a transforaminal epidural injection and/or paravertebral facet joint injection on the same day as an interlaminar or caudal epidural/intrathecal injection sacroiliac joint injection, lumbar sympathetic block or other nerve block is considered not medically necessary. If more than one procedure is provided on the same day, physician/facilities will be paid for only one procedure.

• Therapeutic transforaminal epidural injections exceeding two levels (bilaterally) on the same day will be denied as not medically necessary. A maximum of three levels per region will be paid when billed unilaterally (indicated by appropriate modifier).

• Repeat therapeutic transforaminal epidural injections at the same level in the absence of a prior response demonstrating >50% relief of pain lasting at least six weeks, will be considered not medically necessary.

• Once a diagnostic transforaminal epidural block is negative at a specific level, no repeat interventions should be directed at that level and will be considered not medically necessary unless there is a new clinical presentation with symptoms, signs and diagnostic studies of known reliability and validity that implicate that level.

• Long-term multiple nerve blocks over a period of several weeks/months is not an effective method for chronic pain management – it is generally not considered reasonable and necessary to perform transforaminal epidurals consisting of more than four injections per region per year.

• General or monitored anesthesia is rarely required for these injections – the presence of an anesthesiologist/anesthetist is not considered medically necessary except in rare cases when a patient has a pre-existing unstable medical condition. If the patient is not medically stable and requires the presence of an anesthesiologist/anesthetist to undergo these injections then the procedure should not be performed in the office setting.

• The presence of an anesthesiologist/anesthetist may be required for patients with psychiatric diagnoses if their conditions prevent them from cooperating with the pain management
team during the procedure (such as acute drug or alcohol intoxication or acute confused state) and for those patients requiring unusual sedation or anesthesia.

- Anesthesia services provided as “standby” anesthesia services cannot be billed to the patient.

- Services by an anesthesiologist/anesthetist with administration of anesthesia for administration of these injections in the inpatient, outpatient, or ambulatory facility setting (ASC) where the only indication for the presence of these providers is compliance with hospital or ASC policy, is considered not medically necessary and not eligible for reimbursement.

Evidence Review

Background

Trigger point injection (TPI) is a procedure used for the management of chronic pain. TPI works by injecting a solution of an anesthetic, steroid, and/or anti-inflammatory into extremely painful areas of muscle that contain trigger points or knots of muscle that form when muscles fail to relax. According to the Centers of Medicare and Medicaid (CMS), these trigger points are hyperirritative foci that may be present in any skeletal muscle in response to strain and appear as a knot or tight band of muscle. Compression of the trigger point may elicit tenderness, referred pain or a local twitch response. The goal of TPI is to inactivate the trigger point there by alleviating pain and restoring function to the area. Although trigger points only form in muscle, they can also irritate surrounding nerves and cause pain felt elsewhere in the body. The diagnosis of trigger points requires a thorough history and examination. CMS indicates the following as possible clinical symptoms: history of onset of pain and presumed cause, distribution pattern of pain consistent with pattern of trigger points, range of motion restriction, muscular deconditioning in affected areas, focal tenderness of trigger point, palpable taut band of muscle in which trigger point is located, and reproduction of referred pain pattern upon stimulation of trigger point. Activation of trigger points is thought to be caused by acute or chronic muscle overload, activation by other trigger points, psychological stress, radiculopathy, or infection.

Myofascial pain syndrome (MPS) is a chronic pain condition characterized by the presence of multiple trigger points located in the muscle or surrounding tissue (muscle fascia). TPI is a useful therapy for patients with myofascial pain syndrome who are unresponsive to other less invasive
treatments such as massage, ultrasounds, analgesics, physical therapy, and range of motion exercises.

According to the CMS, a transforaminal epidural injection is a neural blockade technique used in chronic pain management and can be used for diagnostic or therapeutic purposes. The primary diagnostic value of transforaminal epidural injections is to determine whether pain is somatic, visceral, or functional. Therapeutic blocks are performed after the diagnosis is established, and include a local anesthetic test dose to confirm proper placement followed by the injection of anesthetic, antispasmodic and/or anti-inflammatory substances for the long-term control of pain.

A selective block is performed of the cervical, thoracic, lumbar or sacral nerve roots with proximal spread of contrast/local anesthetic through the neural foramen to the epidural space. Imaging is utilized to ensure the needle tip is placed within or adjacent to the lateral margin of a neural foramen. Contrast material is injected to verify correct needle placement, determine abnormal filling patterns consistent with foraminal, lateral recess or nerve root pathology, and to identify unwanted vascular or intrathecal uptake. A small volume of local anesthetic is injected in order to perform a diagnostic, reproducible blockade of a specific nerve root.

CMS recommends a multi-disciplinary or collaborative comprehensive evaluation (eg, orthopedics, neurologist, neurosurgeon, physiatrist, anesthesiologist, pain medicine specialist, and/or attending physician) be conducted prior to initiating a trial of these injections for the relief of chronic pain.

References


**History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/16/19</td>
<td>New policy, approved August 13, 2019, effective January 1, 2020. Trigger Point Injections may be considered medically necessary to treat myofascial pain syndrome, as a bridging therapy to relieve pain and as a single therapeutic maneuver for mechanically blocked joints when criteria are met. Transforaminal epidural injections may be considered medically necessary for the diagnostic and therapeutic indications as listed in this policy.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2019 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy only applies to Individual Plans.
Discrimination is Against the Law

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:
• Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  • Qualified sign language interpreters
  • Written information in other formats (large print, audio, accessible electronic formats, other formats)
• Provides free language services to people whose primary language is not English, such as:
  • Qualified interpreters
  • Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-4535, Fax 425-918-5592. TTY 800-842-5357
Email AppealsDepartmentInquiries@Premera.com

You can also file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
U.S. Department of Health and Human Services
200 Independence Avenue SW, Room 509F, HHH Building
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)

Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost.
Call 800-722-1471 (TTY: 800-842-5357).

Arabic (Arabic):
يكون هذا الإشعار معلومات هامة. قد يكون هذا الإشعار معلومات مهمة بخصوص طبيك أو العلاجية التي تريدها المرضى عليها من خلال Premera Blue Cross. إذا كنت تريدين تدقيق صحية أو التغطية في هذا الإشعار، قد تحتاج إلى إجراء في تأريخ محدد، من خلال كتابة التغطية الصحية أو التغطية في ذلك الكشف. يمكنك الحصول على هذه المعلومات والمساعدة بكلك دون تكبد أي ثمن. اتصل 800-722-1471 (TTY: 800-842-5357) للحصول على معلومات.


Este aviso poderá conter informações importantes. Aqui estão as informações relevantes:


- **Русский (Russian):** Настоящее уведомление содержит важную информацию. Это уведомление может содержать важную информацию о вашем заявлении или страховом покрытии через Premera Blue Cross. В настоящем уведомлении могут быть указаны ключевые даты. Вам, возможно, потребуется принять меры к определенным предельным срокам для сохранения страхового покрытия или помощи с расходами. Вы имеете право на бесплатное получение этой информации и помощь на вашем языке. Звоните по телефону 800-722-1471 (TTY: 800-842-5357).

- **Espanol (Spanish):** Este Aviso contiene información importante. Es posible que este aviso contenga información importante acerca de su solicitud de cobertura a través de Premera Blue Cross. Es posible que haya fechas clave en este aviso. Es posible que deba tomar alguna medida antes de determinadas fechas para mantener su cobertura médica o ayuda con los costos. Usted tiene derecho a recibir esta información y ayuda en su idioma sin costo alguno. Llame al 800-722-1471 (TTY: 800-842-5357).


- **ไทย (Thai):** ประกาศนี้มีข้อสำคัญ ประกาศนี้มีข้อสำคัญเกี่ยวกับการขอความช่วยเหลือประกันสุขภาพของคุณ Premera Blue Cross และข้อกำหนดที่เกี่ยวข้องเกี่ยวกับการขอความช่วยเหลือประกันสุขภาพของคุณ ซึ่งมีการยืนยันความจริง โปรดติดต่อ Premera Blue Cross ที่ 800-722-1471 (TTY: 800-842-5357).

- **Український (Ukrainian):** Це повідомлення містить важливу інформацію. Це повідомлення може містити важливу інформацію про Ваше звернення щодо страхувального покриття через Premera Blue Cross. Зверніть увагу на ключові дати, які можуть бути вказані у цьому повідомленні. Існує імовірність того, що Вам треба буде здійснити певні кроки у конкретні кінцеви строки для того, щоб зберегти Ваше медичне страхування або отримати фінансову допомогу. У Вас є право на отримання цієї інформації та допомоги безкоштовно на Вашій рідній мові. Дозвоніться за номером телефона 800-722-1471 (TTY: 800-842-5357).